SynthesisJAMA oncology2018
Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2016: A Systematic Analysis for the Global Burden of Disease Study.
Synthesis in JAMA oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 9 registered trials, which are not on this map. Cited by 915 papers, 12 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Lenvatinib Combined Pembrolizumab as a Second-line Treatment in Advanced Hepatobiliary Tumors: a Single-center, Single-arm, Non-randomized Clinical Study
Axitinib Plus Toripalimab as Second-line Treatment in Hepatobiliary Malignant Tumors: a Single-arm, Non-randomized, Single-center Phase II Trial
Application of Narrow Band Imaging (NBI) Under Electronic Bronchoscope in the Diagnosis and Staging of Lung Cancer
Development and Evaluation of the Effectiveness of a Multimedia-based Hormonal Therapy Information Program for Patients With Prostate Cancer
Regorafenib Combined With PD-1 Inhibitor Therapy for Second-line Treatment of Hepatocellular Carcinoma: A Single Arm, Nonrandomized, Single Center Clinical Study
Evaluation of HER2-targeted Therapy for Gastric Cancer and Establishment and Verification of Monitoring System
An Open-label, Phase I/IIa Dose Escalation and Expansion Study to Determine the Safety and Clinical Activity of an Immune Priming Cell Therapy (INKmune) in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)
Surgical Strategy of NSCLC Patients After Neo-adjuvant or Induction Treatment
Haploidentical Combined With Cord Blood Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes: A Prospective, Multicenter Clinical Study
Who cites it
915 citing papers in PubMed, 12 syntheses or guidelines pooled it.
- Global Inequities in Unpaid Cancer Caregiving: A Systematic Review and Exploratory Meta-Analysis of Time and Cost Burden.Cancer medicine · 2026Pooled it
- The global burden of migraine and tension-type headache, 1990-2021: a multi-model Bayesian meta-regression with decomposition of age-period-cohort effects, health inequalities, and frontier analysis.Frontiers in neurology · 2026Pooled it
- Stepped-care models for cancer symptom management: a systematic review of efficacy and cost-effectiveness.Journal of the National Cancer Institute · 2026Pooled it
- Exploring the role of cervicovaginal microbiota as risk factor for cervical cancer in Sub-Saharan Africa: a systematic review and meta-analysis : By.BMC women's health · 2025Pooled it
- The effectiveness of play therapy on depression and anxiety in hospitalized children with cancer: a systematic review.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025Pooled it
- A systematic review of health state utility values for older people with acute myeloid leukaemia.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2024Pooled it
- Pooled it
- Does Exercise Improve Health-Related Quality of Life of Colorectal Cancer Survivors? A Systematic Review and Meta-Analysis.Asian Pacific journal of cancer prevention : APJCP · 2024Pooled it
- Pooled it
- Effect of different anaesthetic techniques on the prognosis of patients with colorectal cancer after resection: a systematic review and meta-analysis.Frontiers in oncology · 2024Pooled it
- The prevalence of anxiety symptoms/disorders in cancer patients: a meta-analysis.Frontiers in psychiatry · 2024Pooled it
- Impact of interventions on the quality of life of cancer patients: a systematic review and meta-analysis of longitudinal research.Health and quality of life outcomes · 2023Pooled it
- Palbociclib, a Selective CDK4/6 Inhibitor, Administered Before and After Chemoradiotherapy for Human Papillomavirus-Negative, Locally Advanced Head and Neck Squamous Cell Carcinoma: A Single-Arm, Phase II Trial.JCO precision oncology · 2025Trial
- Ramucirumab in combination with pembrolizumab for recurrent or metastatic head and neck squamous cell carcinoma: a single-centre, phase 1/2 trial.The Lancet. Oncology · 2024Trial
- Trial
- Global burden of esophageal cancer attributable to smoking and alcohol, 1990-2021, with projections to 2040: a population-based analysis of the global burden of disease study 2021.Annals of medicine · 2026Observational
- Trends and cross-country inequalities in the global burden of thyroid cancer, 1990-2021: A population-based study.Medicine · 2026Article
- Global, regional, and national analysis of CNS cancers burden from 1990 to 2021 and forecast of disease trend over the next 25 years.Medicine · 2026Article
- Provider-initiated screening clinical breast examination and patient navigation in sub-Saharan Africa: protocol for an implementation mapping-based pilot study.Implementation science communications · 2026Article
- Loss of hepatocyte PI3Kα reduces hepatocellular carcinoma and hepatocyte proliferation in association with altered lipid metabolism.JHEP reports : innovation in hepatology · 2026Article
855 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
154 authors.
Funding
Abstract
Importance: The increasing burden due to cancer and other noncommunicable diseases poses a threat to human development, which has resulted in global political commitments reflected in the Sustainable Development Goals as well as the World Health Organization (WHO) Global Action Plan on Non-Communicable Diseases. To determine if these commitments have resulted in improved cancer control, quantitative assessments of the cancer burden are required. Objective: To assess the burden for 29 cancer groups over time to provide a framework for policy discussion, resource allocation, and research focus. Evidence Review: Cancer incidence, mortality, years lived with disability, years of life lost, and disability-adjusted life-years (DALYs) were evaluated for 195 countries and territories by age and sex using the Global Burden of Disease study estimation methods. Levels and trends were analyzed over time, as well as by the Sociodemographic Index (SDI). Changes in incident cases were categorized by changes due to epidemiological vs demographic transition. Findings: In 2016, there were 17.2 million cancer cases worldwide and 8.9 million deaths. Cancer cases increased by 28% between 2006 and 2016. The smallest increase was seen in high SDI countries. Globally, population aging contributed 17%; population growth, 12%; and changes in age-specific rates, -1% to this change. The most common incident cancer globally for men was prostate cancer (1.4 million cases). The leading cause of cancer deaths and DALYs was tracheal, bronchus, and lung cancer (1.2 million deaths and 25.4 million DALYs). For women, the most common incident cancer and the leading cause of cancer deaths and DALYs was breast cancer (1.7 million incident cases, 535 000 deaths, and 14.9 million DALYs). In 2016, cancer caused 213.2 million DALYs globally for both sexes combined. Between 2006 and 2016, the average annual age-standardized incidence rates for all cancers combined increased in 130 of 195 countries or territories, and the average annual age-standardized death rates decreased within that timeframe in 143 of 195 countries or territories. Conclusions and Relevance: Large disparities exist between countries in cancer incidence, deaths, and associated disability. Scaling up cancer prevention and ensuring universal access to cancer care are required for health equity and to fulfill the global commitments for noncommunicable disease and cancer control.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.